BIIB vs CVS: fair value comparison
Biogen Inc. and CVS Health Corporation · Updated 2026-08-31
BIIB currently screens as fairly valued while CVS screens as overvalued. Within Healthcare, BIIB currently sits closer to the top of our discount ranking. BIIB carries the stronger quality grade.
| BIIB | CVS | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $218.50 | $93.06 |
| 12-month range | $139.63–$202.95 | $72.49–$105.37 |
| Sector rank | #83 of 113 Healthcare | #88 of 113 Healthcare |
| Quality grade | B | F |
| Momentum grade | A | — |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BIIB fair value analysis · CVS fair value analysis